ARQT Arcutis Biotherapeutics Inc

$ARQT this is what we were expecting after the last ER. The MMs had to steal their shares before running it up.

$ARQT I only bought this stock because after almost two decades of dealing with sebherroic dermatitis, Zorvey is the first drug that actually works!

$ARQT $IOVA $NVO this morning Novo ok ☑️ few hours and let’s see arcutis. Iovalove: For tomorrow morning I’m super nervous cause it’s gonna be tough but if they show good numbers and give us little clarity around lung conference I’m fine long term 🥹

$ARQT -17% for what? Cash positive, raised guidance, huge investment in mktg with main names, atm 200 mln is not an offering and maybe they don’t need at all, a lot of readout and 1 fda approval just in 3 months. One of the best launch I’ve ever seen…-17%

$ARQT Quiet around here for earnings day! Over the past month or two one of the better performing stocks around! 34-35? Lets go!!

$ARQT They just announced a $200,000,000 stock offering, aka massive shareholder dilution, after their stunning $.06 Earnings MISS of analyst’s Q3 profit estimates of $.12 EPS BY 50%. The secondary offering was not priced on a share price basis in the news release, but typically it’s all a done deal prior to announcement. We will know more Thursday morning. But it’s unlikely that the news will be motivating investors to buy more shares in the near term.

$ARQT Nobody is talking about $ARQT. Today it ripped +10.6% to a 52-week high on 3x volume. A +59% grower. BlackRock just opened a $276M position. Here's what the institutions knows that you don't. Whale check 🐋 BofA added $78M. Jupiter and Bamco opened new stakes too. Over 100% institutionally owned. The big money is buying, not leaving. The growth is real: Q2 revenue $130M, +59% YoY. Beat on both lines. First profitable quarters just printing. FY guide raised to $525–540M. The highest grower on the list. Zoryve scripts feed the guide. The average target sits well above the stock. The fresh initiation sits way above that. Long Term: branded dermatology is expanding and Arcutis is taking share. Levels: $31–31.50 zone. Below $28.82, I'm wrong. If this thesis plays out, Q3 confirms the guide and the initiation math takes over. The trend stays up. The breakout holds. If it closes below $28.82 instead, forget everything above. Educational only. Not financial advice.

TD Cowen⬆️ $ARQT's PT to $40 from $35 and reiterated at Buy after the Co. reported its earnings. [ROIV $INCY PFE AMGN ABBV JNJ UCBJY BMY OGN SNY - REGN NVS] Here's what TD Cowen said in its note: Zoryve sales of $144MM were roughly in-line with cons, driven by broad-based demand growth across the cream and foam, with revenue up 11% Q/Q and 45% Y/Y. 2026 guidance was raised to $535-545MM reflecting sustained momentum as GTN improves modestly. Near-term upside centers on YE vitiligo Phase II data, where a faster onset, QD dosing, and no boxed warning could differentiate Zoryve from Opzelura.

$ARQT Well, current market is indeed the main reason for the drop but do we really need an increase of $16 mil. for marketing and celebrity campaign on top of $8 mil. increase in sales personnel costs?

$ARQT $IOVA $NVO Novo 👍 Arcutis 👍 BUT market us stupid and a Stellar earning and a huge growth story became a drop today Iovance next…few hours

$ARQT Arcutis Biotherapeutics part of #IBD "Profitable Biotech" closed today at the highest levels in 5 yrs, exceeding base since late '25. While many sectors continue to show evidence of being under severe pressure in a way that will lead many to likely still require consolidation in Nov even on a bounce in late Oct, many parts of HC have come to life and a MUST to pay attention to this rotation.

Latest analyst update, October 19, 2026: An analyst kept its Buy rating on Arcutis and raised its price target to $44 from $38 (a third-party opinion, not a recommendation). Arcutis ($ARQT) Stock Hub: ZORYVE Revenue Grew To $129.9 Million In The Second Quarter, With Index Entry Done And The February PDUFA Ahead Not investment advice. More details in our stock hub.

$ARQT The $200,000,000 secondary offering announcement is essentially the official establishment of an ATM for creating the flexibility of selling up to $200M worth of shares at any time without notice to raise additional capital should management determine AT SOME FUTURE DATE that they need additional cash on hand for corporate purposes. It is NOT an issuance of new shares at this time.

$ARQT everybody here posted "market fault" , like if an abstract entity controls WS , instead are SOB. MF , POS doing this !!! Last ER was excellent , and this was absolutely flat , now with a little correction -16% !!! I'M SICK OF THIS !!!

$ARQT The street sold off arqt b/c they're confusing it with this: Company Name Confusion: A similarly named biotech firm, Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), recently completed an underwritten public offering of its common stock to raise gross proceeds of approximately $200 million. ARQT is profitable. Generating cash on growing sales. They don't need this cash.

$ARQT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.06 • Reported revenue of $143.92M up 45.05% YoY

Ticker SCAG news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG only 1.3 million shares float - Chinese - On watch. $ARQT (

$ARQT The MM Mafia desperately needs sellers to cover their estimated 45+ million counterfeit share open naked short positions. (Add Imstitutional short positions of 20 million shares and the entire retail investor inventory of shares bc institutional ownership alone is 112.5% of all issued shares), because the Mafiosi only get sellers by dropping their Bid & Ask.